Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 8, 2022Journal of Antimicrobial Chemotherapy

Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study)

View Full Paper
Ask AI
Bookmark
Share

Authors

JCJuan José CastónInstituto de Salud Carlos IIIÁCÁngela CanoInstituto de Salud Carlos IIIIPInés Pérez‐CamachoHospital Regional Universitario de Málaga

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Castón et al. (2022) studied this question.

synapsesocial.com/papers/6ab347d5dccdd7a5f560d959https://doi.org/10.1093/jac/dkac049
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ceftazidime-Avibactam To Treat Life-Threatening Infections by Carbapenem-Resistant Pathogens in Critically Ill Mechanically Ventilated Patients2019 · 90 citations
  2. 2Modified Carbapenem Inactivation Method for Phenotypic Detection of Carbapenemase Production among Enterobacteriaceae2017 · 404 citations
  3. 3Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae2017 · 662 citations
  4. 4Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program2016 · 394 citations